Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence

Publisher： Bentham Science Publishers

E-ISSN： 2212-389x|1|2|219-226

ISSN： 1574-3624

Source： Current Signal Transduction Therapy, Vol.1, Iss.2, 2006-05, pp. : 219-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. : 897-906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adverse effects of androgen‐deprivation therapy in prostate cancer and their management

By  

BJU INTERNATIONAL, Vol. 115, Iss. S5, 2015-04 ,pp. : 3-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Androgen Deprivation Therapy in Prostate Cancer - Current Status in M1 Patients

By  

Oncology Research and Treatment, Vol. 38, Iss. 12, 2015-0 ,pp. : 646-652

Karger

Access to resources Recommend Favorite

Psychological effects of androgen‐deprivation therapy on men with prostate cancer and their partners

By  

CANCER, Vol. 121, Iss. 24, 2015-12 ,pp. : 4286-4299

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolic changes in patients with prostate cancer during androgen deprivation therapy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 25, Iss. 1, 2018-01 ,pp. : 45-53

John Wiley & Sons Inc

Access to resources Recommend Favorite